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Roles and responsibilities: 
 
Funder:  
The National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) and 
Research for Patient Benefit Programmes provide financial resources for the conduct of the trial, 
provides on-going support to the Chief Investigator (CI) to ensure that the trial progresses smoothly 
and monitors progress against key milestones via the submission of regular progress reports.   
 
Trial Sponsor:    
Guy’s and St Thomas’ (GST) NHS Foundation Trust, Guy’s Hospital, Great Maze Pond, London SE1 
9RT, and King’s College London (KCL), Strand, London, WC2R 2 LS 
 
The funder and sponsor both approve protocol amendments prior to submission for 
ethical/regulatory approval. The funder and sponsor will not have a role in the analyses and 
interpretation of the data or the decision to submit the results. 
 
Role of trial sponsor:  
GST and KCL have agreed to take on the joint role of Co-sponsor for the study. The Co-Sponsors act 
as Sponsor for the trial under the Research Governance Framework for Health and Social Care, and 
the Medicines for Human Use (Clinical Trial) Regulations 2004 and Amended Regulations 2006. The 
Co-Sponsors have delegated trial management activities to the King’s Health Partners Clinical Trials 
Office (KHP-CTO) and the Clinical Trials Research Centre (CTRC), University of Liverpool. The sponsors 
will at all times maintain adequate insurance in relation to the study. KCL, through its own 
professional indemnity (Clinical Trials) and no fault compensation and the GST NHS Foundation Trust 
having a duty of care to patients via NHS indemnity cover, in respect of any claims arising as a result 
of clinical negligence by its employees. 
 
Role and responsibilities of the Trial Coordinating Centre:   
TREAT is co-ordinated by the CTRC at the University of Liverpool. The Co-Sponsors have delegated 
the trial management activities along with trial data management, statistics and information systems 
to the CTRC.  
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Role and responsibilities of the Trial Oversight Committees: 
The study has an independent Trial Steering Committee (TSC) (comprising independent members as 
well as the Chief Investigator as voting members) and an Independent Data & Safety Monitoring 
Committee (IDSMC). Day to day oversight is conducted by the Trial Management Group (TMG), 
chaired by the Chief Investigator. The roles and responsibilities of the committees are defined in the 
TSC Terms of Reference and the IDSMC Charter, available upon request. 
 
 
What’s already known about this topic? 
 Oral systemic immuno-modulatory medication is regularly used off-licence in 
children with severe atopic eczema. 
 Ciclosporin (CyA) is the commonest first line systemic agent used in this context, but 
Methotrexate (MTX) has emerged as an important therapeutic alternative. 
 There is currently no adequately powered randomised controlled trial that compares 
both treatments in children. 
 
What does this study add? 
 TREAT addresses this gap and compares the effectiveness, safety, cost-effectiveness 
and impact on patient’s quality of life of these two drugs. 
 TREAT also examines the effects of both drugs using systemic and cutaneous 
markers of inflammation and the effect of filaggrin (FLG) genotype and T cell 
cytokine signatures on treatment response.  
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Abstract: 
 
Background:  Oral systemic immuno-modulatory medication is regularly used off-licence in children 
with severe atopic eczema. However, there is no firm evidence regarding the effectiveness, safety, 
cost-effectiveness and impact on quality of life from an adequately powered randomised controlled 
trial (RCT) using systemic medication in children. 
 
Patients/Methods: Multi-centre, parallel group, assessor-blind, pragmatic RCT of 36 week duration 
with a 24 week follow-up period. 102 children aged 2-16 years with moderate to severe atopic 
eczema, unresponsive to topical treatment will be randomised (1:1) to receive methotrexate (MTX; 
0.4mg/kg per week) or ciclosporin (CyA; 4mg/kg/day). The trial has co-primary outcomes: change 
from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to 
first significant flare following treatment cessation.  
 
Analysis plan: The main aims of the trial are to assess whether there is a difference in the 
speed of onset, effectiveness, side-effect profile and reduction in flares post-treatment 
between CyA and MTX, and, also the cost-effectiveness of the drugs. Treatment impact on 
quality of life will also be examined as well as whether FLG genotype influences treatment 
response. In addition, the trial studies the immune-metabolic effects of CyA and MTX. 
 
Conclusions: The TREAT trial addresses important therapeutic questions, highlighted in systematic 
reviews and treatment guidelines for atopic eczema. The trial design is pragmatic to reflect current 
clinical practice. 
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Background 
Atopic eczema (syn. ‘atopic dermatitis, ‘eczema’) is a chronic, pruritic inflammatory skin disease, 
affecting around 20% of UK children, 16% of whom have moderate-severe disease.1 It comes at a 
high cost, for patients and families as well as society.2,3 Severe atopic eczema is often accompanied 
by significant sleep disturbance, poor school attendance and social withdrawal, as well as attention-
deficit hyperactivity disorder, anxiety and clinical depression.4 Skin infections are also common in 
poorly controlled atopic eczema and a reason for hospital admission.4  
 
Although most cases of atopic eczema are adequately controlled with emollients, topical anti-
inflammatory treatments and/or ultraviolet (UV) therapy, around 2% of children require oral 
immuno-suppressive treatment to induce and maintain disease control.5 There are, however, only 
limited systemic treatment options available and there is concern about their potential short- and 
long-term side effects.5 The treatment of severe atopic eczema in children taskforce survey in 765 
consultant dermatologists and paediatricians from 8 European countries was conducted to establish 
which systemic treatment options are available.6 This showed that the first choice systemic immuno-
suppressive agent was overall ciclosporin (CyA) with 43%, compared to the UK where 39% use 
azathioprine (AZA) and 35% use CyA.6 Although MTX was only the third most commonly used 
systemic treatment in the survey in the UK, it is increasingly being used as a first line systemic agent 
in children, as shown by our most recent treatment survey in the US.7 Furthermore, while there is 
significant concern about the long-term prescribing of CyA (renal toxicity) and AZA (in particular 
lymphoma and progressive multifocal leukoencephalopathy), MTX is generally considered well-
tolerated and safe in the long-term.5,8 In addition, two RCTs and their follow up studies suggested no 
significant difference in efficacy between MTX and AZA in adults and MTX and CyA in children, even 
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if CyA appears to show its treatment effect more quickly.8-11 However, these studies were 
statistically underpowered.12  
 
There is therefore a clear need to compare MTX with the most established immuno-suppressive 
medication, CyA, which has also been highlighted in a systematic review.13 Both drugs have 
demonstrated a reduction in atopic eczema severity and improve quality of life.4,5,14  
 
The protocol for the trial is presented here and has been written in accordance with the 
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.
15
  
 
Objectives:  
The primary objectives are to compare the safety and efficacy of MTX versus CyA, in recalcitrant 
atopic eczema in children, during 36 weeks of treatment and to compare disease control post-
treatment cesssation (time to return to baseline disease severity) over the 24 weeks follow-up 
period.  Secondary objectives are to examine i) the number of flares during the trial period as well 
disease severity throughout follow up, ii) the impact on quality of life, iii) the effects of both drugs 
using novel systemic and cutaneous markers of inflammation during treatment, iv) the effect of 
filaggrin (FLG) genotype and T cell cytokine signatures on treatment efficacy, v) the side-effect 
profiles of both drugs, and vi) a comparison of the cost effectiveness of both drugs in a health 
economic evaluation.  
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Patients and methods 
Trial design and study setting 
TREAT is a phase III multi-centre, parallel group, assessor-blind, pragmatic RCT aiming to recruit 102 
children. Study sites are in 13 secondary and tertiary care Paediatric Dermatology Departments 
across the UK and Ireland (Supplementary Table S1). 
 
Children are identified in the paediatric dermatology clinics at the study sites. Inclusion criteria 
include (see full criteria in Table 1): (i) age 2-16 years; (ii) severe recalcitrant atopic eczema, defined 
as an inadequate clinical response to moderate (face) to potent (body) topical CS and an o-SCORAD 
severity score ≥30, and (iii) residence within travelling distance of the recruiting centre.  Exclusion 
criteria include (see full criteria in Table 2): (i) serious underlying medical condition; (ii) previous 
exposure to systemic immuno-suppressive or biologic agent(s); (iii) recent use of oral CS, 
phototherapy or live vaccines.   
 
Interventions 
Participants are randomised to either oral/subcutaneous MTX or oral CyA using an allocation ratio of 
1:1 and will receive the trial drug for a period of 36 weeks and are followed up for a further 24 
weeks following treatment cessation.  
 
CyA and MTX are commonly used in children for other chronic inflammatory conditions.  For 
instance, for severe paediatric psoriasis a dose of 0.4mg/kg/week MTX (max 25mg per week) is used, 
as in the TREAT trial (Children’s British National Formulary).16 The Children’s British National 
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Formulary stipulates a maximum dose for CyA for severe atopic eczema of 5mg/kg/day, while a dose 
of 4mg/kg/day is used in the TREAT trial based on the TREAT survey results.6  
 
Supplementary Table S2 (supplementary appendix) summarises the formulations of MTX and CyA 
used in the study. The assessor who will perform the severity assessments will be blinded to the trial 
allocation. 
 
Ciclosporin (Neoral brand) 
Participants are prescribed 4mg/kg/day given in two divided doses for the treatment period of 36 
weeks. After 12 weeks, dose increases (to a maximum of 5mg/kg/day) or decreases are allowed, 
dependent on treatment response. Dose modifications according to blood pressure and blood test 
results are detailed in Supplementary Table S3 (supplementary appendix). As Neoral is the only 
brand with both liquid and capsule preparations, the brand Neoral was selected for TREAT. 
 
Methotrexate 
Participants are prescribed an initial test dose of 0.1mg/kg at week 0 and then the therapeutic dose 
of 0.4mg/kg/week (maximum dose 25mg/week) until week 12, providing there are no significant 
side effects and safety blood tests results (see Supplementary Table S4 (supplementary appendix)).  
After week 12, dose modifications according to treatment response are allowed (maximum dose 
25mg/week). Only the 2.5mg strength of MTX tablet will be prescribed and dispensed. Subcutaneous 
administration is available to those who suffer significant gastrointestinal intolerance. Participants 
on the MTX arm will also be prescribed folic acid 1mg once daily apart from on the day of MTX 
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administration. Dose modifications according to blood pressure and blood test results are detailed in 
Supplementary Table S5 (supplementary appendix). 
 
Adherence 
Participants are instructed to return unused medication, which will be counted and recorded on the 
accountability log prior to being disposed/destroyed according to local NHS policy. If for any reason 
a participant misses a treatment dose, this will be documented in the participant diary. 
 
Potential side effects 
CyA’s main potential side-effect is an increase in blood pressure and nephrotoxicity. Regular blood 
pressure and renal function measurements are therefore mandatory in routine clinical care. To 
assess renal function more carefully both plasma creatinine and cystatin C levels are measured in 
TREAT (at baseline, 2, 8, 12, 36, and 60 weeks) as well as urinary tubular N-acetyl-beta-D-
glucosaminidase (at baseline, 2, 12, 36 and 60 weeks), a sensitive marker of renal tubular function.17 
 
As for MTX, gastrointestinal disturbance (e.g. nausea), liver function abnormalities and bone-marrow 
suppression are the main potential side effects. Based on both paediatric dermatology and 
rheumatology experience, however, MTX appears to be generally well-tolerated and safe in children, 
even in settings where higher doses are used, often for prolonged time periods and in combination 
with biologics.4,5,18-21 In TREAT, safety  
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bloods are taken one week post MTX test dose to capture rare idiosyncratic reactions. In addition, 
children in both study arms have safety bloods every two weeks for the first month, then monthly 
until week 12 and then eight-weekly thereafter while on treatment, in keeping with the American 
Academy of Dermatology guidelines for the use MTX and CyA in children with severe atopic 
eczema.22 
 
Drugs known to interact with CyA or MTX may be prescribed when considered necessary for the 
patient's safety and well-being. If concomitant drugs are given, careful monitoring for drug-related 
adverse effects is recommended, as would be the case in clinical practice. Since CyA is metabolised 
by cytochrome p450 (CYP3A) isoenzymes, in particular CYP3A4, drugs known to significantly alter 
plasma or whole blood concentrations of CyA through this route are prohibited during the study. 
 
Concomitant medication 
Participants will continue on their standard eczema care in line with National Institute for 
Health and Care Excellence (NICE) guidance, including regular emollients, (antiseptic) bath 
additives and mild-to-potent topical corticosteroids (TCS), topical calcineurin inhibitors and 
oral antihistamines of the patient’s/local investigator’s choice. Rescue oral antibiotics and 
oral corticosteroids are also permitted. Any medication required for any ongoing illness and 
any rescue medications are recorded both during the treatment and follow up period. Use of 
wet wraps or other occlusive dressings are prohibited throughout the study period. 
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Outcomes 
Primary outcomes:  
Two primary outcomes are assessed: 
1. The change in atopic eczema severity between baseline & 12 weeks of treatment in 
the two treatment arms using the –o-SCORAD, and 
2. Time to first flare (defined as time to return to baseline or worse o-SCORAD score) 
during the 24 weeks after treatment cessation in the MTX vs CyA groups. 
 
Secondary outcomes: 
1. To examine atopic eczema severity using validated severity scores: Eczema Area and Severity 
Index (EASI), Investigators Global Assessment (IGA), o-SCORAD and Patient Orientated Eczema 
Measure (POEM) scores between 0 and 12, 36, 48, 60 weeks; 
2. To compare the number of flares in each study arm as well as the proportion of children who re-
flared during the 24 weeks after treatment cessation; 
3. To study the impact on quality of life through change in Children’s Dermatology Life Quality Index 
(CDLQI, children age ≥4 years), Infant’s Dermatology Quality of Life Index (IDQOL, children <4 years 
of age), Dermatitis Family Index (DFI) and Child Health Utility 9D (CHU-9D) scores between 0, 12, 36, 
48 and 60 weeks; 
4. To determine the proportion of participants achieving 50% improvement in the o-SCORAD and 
EASI index at 12, 36, 48, and 60 weeks; 
5. The difference in the proportion of participants withdrawing from treatment due to adverse 
events; 
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6. To assess the cost-effectiveness of CyA vs MTX; 
7. To study the immuno-metabolic effects of MTX and CyA, especially in relation to markers of 
glycolytic activation and T cell cytokine signature, at baseline, during treatment and up to 24 weeks 
after completion of treatment; 
8. To compare the drug side effects/toxicity profiles of both MTX and CyA;  
9. To examine the association between MTX polyglutamate and CyA trough levels and reduction in 
atopic eczema severity as well as drug-related side effects; and 
10. To study the impact of FLG genotype (yes/no) on reduction in atopic eczema severity. 
 
Sample size 
Randomising a total of 102 participants, 51 into each of the study arms, satisfies both of the 
following sample size calculations. For the first primary outcome (o-SCORAD), the change from 
baseline to 12 weeks will be calculated for each participant. The study aims to detect a minimum 
clinically important difference (MCID) of 8 o-SCORAD points between the two treatment groups, 
assuming a standard deviation (SD) of 10 (based on the only other paediatric RCT with systemic 
immuno-suppressive medication in children which saw a SD of 6.3 (MTX arm) vs 8.9 (CyA arm) at 12 
weeks)7 a sample size of 41 per group, increasing to 49 per group to allow for an estimated 18% loss 
to follow up, will be required to provide 90% power using a t-test with a 0.025 two-sided significance 
level. The co-primary outcome of this trial is whether or not a patient re-flares following treatment, 
as this may be an important factor influencing potential change in prescribing behaviour. The 
number of patients on CyA burst treatment who went into remission after three months of 
treatment in the study by Harper et al was three out of 21, indicating that 86% of patients re-
flared,23 assuming a similar flare risk in our CyA group. A sample size of 43 in each group (51 in each 
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group with estimated loss to follow up of 18%) will have 80% power to detect a reduction in re-flare 
of 30% (from 86% to 56%), using a two-sided test with a 0.025 significance level.  
 
Recruitment 
Participants will be identified by the clinical team at each centre via a search of the patient 
database/s or clinic list review. At the routine clinic visit, the patient will be provided with verbal and 
written information about the study and instructions on how to proceed if they are interested in 
taking part. All patients will be provided with a full explanation of the trial, before informed written 
consent/assent is taken.  
 
Consent 
Age-appropriate participant information sheets are provided for parents/guardians and 
children (available upon request). The process of obtaining patient assent and parent/guardian 
informed consent is in accordance with the Research Ethics Committee guidance, and Good 
Clinical Practice (GCP). The investigator, or their nominee (medically qualified physician), 
and the participant and/or parent/guardian sign and date the consent form, before the 
participant can participate in the study. No trial-specific procedures are conducted before 
informed consent has been obtained, and participants are reminded that they may withdraw 
from the trial at any time without it affecting the quality of their care in the future. 
Information on the collection, storage and use of the trial samples is provided in the 
participant information sheets and consent form.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Confidentiality   
Data that contain names or other participant identifiers, such as informed consent forms, will 
be stored separately from the case report forms, questionnaires and patient diaries identified 
by screening/randomisation numbers. The database will be secured with password-protected 
access systems. Individual participant medical information obtained as a result of this study is 
considered confidential. Participants’ study information will not be released outside of the 
study without the written permission of the participant, except as necessary for monitoring by 
authorised individuals (i.e. CTRC, Sponsor, Regulatory Authorities, and NHS Trust) which is 
clearly stated in the consent form. The CTRC will preserve the confidentiality of participants 
taking part in the study and The University of Liverpool is registered as a Data Controller 
with the Information Commissioners Office. 
 
Screening visit 
Informed consent can be taken at or prior to the screening visit, just prior to assessments. 
Patients are assigned a screening number for use on study documentation until randomisation 
takes place. At screening, a full medical history is taken, with review of concomitant 
medication and full assessment against the eligibility criteria as well as a pregnancy test, 
where indicated. An o-SCORAD is completed together with safety bloods. As a safety 
measure, some patients may require a chest x-ray at the screening visit if there is a risk of TB 
exposure, with a radiology report of clear/normal chest X-ray needed before randomisation 
occurs. Patients who fail screening, based on the inclusion/exclusion criteria (see Tables 1 & 
2), can be invited for re-screening after 14 days, if appropriate. 
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Baseline visit 
The baseline visit will occur within a maximum of 14 days of the screening visit. However, 
the screening and baseline visit can be carried out on the same day. At this visit, informed 
consent status is checked, as is eligibility and a review of concomitant medication. As per 
Table 3, the clinician conducts a physical examination and the blinded assessor completes an 
o-SCORAD, EASI and IGA. An additional pregnancy test will be performed where 
indicated. The parent and child complete QoL questionnaires, POEM, Health related QOL 
during the visit and are given a patient diary (including POEM) to complete at home. Blood 
and urine samples are collected for safety screening and FLG genotyping and skin tape strips 
for mechanistic work. (Tape strips and mechanistic bloods are not collected at all sites.) All 
participants who provide consent and fulfil the eligibility criteria (confirmed by a medically 
qualified physician) will be randomised by the Local Investigator or their nominee and either 
CyA or MTX are dispensed. 
 
Randomisation method 
Participants will be randomised to receive MTX or CyA in a 1:1 ratio at the baseline visit. 
Randomisation lists will be generated by an independent statistician using a computer 
generated randomisation schedule stratified by site, using a secure (24-hour) web-based 
randomisation programme controlled centrally by the CTRC. The block sizes will not be 
disclosed in order to ensure allocation concealment.  
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Participant timeline 
Once the participant is randomised to their allocated treatment during the baseline visit (week 0), 
each participant will be enrolled for 60 weeks (36 weeks treatment, followed by a 24 week 
observational period).  Details of the timeline for participants are summarised in Figure 1. 
 
Blinding 
Blinding of the local investigator, research nurse and the participant will not be possible, as CyA is 
given in two divided doses daily and MTX only once a week, but the severity assessors (o-SCORAD, 
EASI & IGA), are blinded to treatment allocation. At each visit, data are collected as to whether or 
not the assessment is made blinded. These data are monitored centrally and reviewed on a regular 
basis. 
 
Visit schedule 
The schedule for assessments during the treatment and the follow-up phase are shown in Table 3. 
 
Participant retention 
Participants may withdraw from treatment if the parent/legal representative (or the participant 
where applicable) withdraws consent, develops an unacceptable toxicity based on the Local 
Investigators judgement, development of illness preventing further treatment or any change to 
the participant’s condition that justifies the discontinuation of treatment. If a participant 
withdraws from trial treatment then centres will explain the importance of remaining on trial 
follow up to allow complete data capture. 
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Safety reporting 
The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031) definitions of an 
adverse event (AE), adverse reaction (AR), serious adverse event, serious adverse reaction and 
suspected unexpected serious adverse reaction will be used during the course of the trial. All 
adverse events will be reported from randomisation until four weeks after treatment cessation. 
Non-serious ARs and AEs should be reported to the CTRC within seven days of the site being made 
aware of the event. Serious ARs/SAEs/SUSARs should be reported to the CTRC within 24 hours of the 
site being made aware of the event. SUSARs will be reported to the MHRA by the KHP CTO and CTRC 
will notify main REC of all SUSARs. All investigator will be informed of all SUSARS occurring 
throughout the course of the study. 
 
Mechanistic studies 
Immunological parameters will be studied to see if there are significant changes in the percentages 
of regulatory T cells, pro/anti-inflammatory cytokine-expressing CD4+ T  
 
cells, or in the corresponding levels of these cytokines in serum following treatment. Comparison will 
be made between MTX vs CyA treated patients, and investigation as to whether there is a 
correlation between cytokine levels and treatment response at 12 and 36 weeks and the risk of re-
flares at 60 weeks. 
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Systemic metabolic and local skin inflammatory parameters will be studied to see if the initial 
treatment response at 12 weeks to MTX (vs CyA) is already associated at that stage with differences 
in the systemic metabolic profiles (shift from pro-inflammatory glycolytic activation to an anti-
inflammatory metabolic profile), and whether this is also seen at 36 and 60 weeks, explaining a more 
sustained disease remission following MTX (vs CyA) therapy. Assessment will include whether 
observed systemic metabolic changes are associated with corresponding inflammatory profiles in 
the skin. Mechanistic blood samples will only be collected from sites that can transport (via courier) 
samples to the KCL biobank facility by 4pm on the same day (within maximum of six hours post 
venesection). 
 
Data management 
Each centre will undertake training in study requirements before being allowed to open to 
recruitment. This will include training on taking informed consent, completion of CRFs, 
randomisation and safety reporting. Specific training will also be given on the severity assessment 
measures and quality of life questionnaires.  
 
The case report forms (CRF) are the primary data collection instrument and are sent to CTRC with 
copies retained at site. A full description of the data management procedures are provided in the 
‘Data Management Plan’ and the ‘Data Entry and Cleaning Manual’, which can be made available 
upon request. All identifiable patient data is pseudonymised and source data are collected in the 
patients’ medical records. Templates of the data collection tools completed by the study site and/or 
participant, including CRFs and questionnaires, are available upon request. 
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Statistical analysis 
A separate statistical analysis plan is available upon request, which details all analyses to be 
conducted for both the primary and secondary outcomes and also the methods that will be 
used to handle missing data and sensitivity analyses. Below is a brief summary of these 
analyses. 
 
The primary analysis will be by intention-to-treat, based on all randomised participants, as far 
as is practically possible. The analysis of change in o-SCORAD from baseline to 12 weeks 
will be examined using analysis of covariance with treatment group and baseline 
measurements as covariates.  Analysis of time to first flare post treatment cessation will be 
summarised by Kaplan-Meier curves for each treatment group and compared overall, using 
the log rank test and survival regression methods. 
 
For the secondary outcomes, continuous data will be reported as the difference in means and 
will be analysed using ANCOVA where appropriate and binary data will be reported in terms 
of relative risk with appropriate 95% confidence intervals.  Missing data will be monitored 
and strategies developed to minimise its occurrence.  The robustness of the complete case 
analysis will be assessed using various imputation assumptions; however these will be 
informed by data collected on the reasons for missing data. 
 
This trial will contain an internal pilot study, to check the assumptions made in the sample 
size calculation. After the primary outcome data are available from 25 patients (o-SCORAD 
index at 12 weeks) the standard deviation of the 25 scores, and the 95% confidence limits for 
this estimate, will be calculated without unblinding allocation. If the 95% confidence limits 
of the estimate of the standard deviation (SD) of the o-SCORAD index at 12 weeks overlap 
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10 the trial will continue unchanged. If the upper 95% confidence limit of the estimate of the 
SD of the o-SCORAD index at 12 weeks is less than 10 the trial will continue unchanged but 
the Trial Steering Committee (TSC) will be informed that the trial power is greater than 
planned. If the lower 95% confidence limit of the estimate of the SD is greater than 10 the 
study is underpowered. The funder will then decide whether to invite an extension or close 
the study. 
 
Cost-effectiveness analyses 
A within-trial cost-effectiveness analysis will be conducted to assess whether CyA offers value for 
money compared to MTX for children with moderate-to-severe AE using standard methodology24-26 
and in accordance with the NICE reference case.27 It will seek to: 
 
 Estimate resource use and costs in severe paediatric atopic eczema in the MTX compared to 
the CyA arm. 
 Estimate the Quality-Adjusted Life Years (QALYs) in severe paediatric atopic eczema in both 
arms. 
 Undertake cost-effectiveness and cost-utility analyses to assess which treatment represents 
best value for money for NHS provision. 
 Estimate uncertainty levels surrounding the decision on which treatment to provide. 
 
We will monitor levels of resource use associated with both interventions including drug costs, 
monitoring costs and adverse event costs over the 36 weeks treatment period. In addition, other 
potentially atopic eczema-related NHS resource items, including primary care visits, prescriptions, 
and other health care contacts will be recorded in participant diaries at baseline and weeks 4, 8, 12, 
20, 28, 36, 48 and 60. We will attach appropriate unit costs to resource use data using published 
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sources for a common price year28-30 to estimate the mean overall cost per participant per study 
arm. Separately, we will record the time-off work parents take because of their child’s atopic eczema 
and cost this using the human capital approach using published average wages31. Children’s time 
away from school will be recorded in units of time but not monetarised. 
 
The economic evaluation will estimate the mean incremental cost and mean incremental effect of 
MTX compared to CyA (separate mean incremental effects will be estimated for: CHU-9D (QALY 
gain); change in o-SCORAD; and flare number). The base case analysis will be the cost-utility analysis 
where QALY for the trial period (based upon CHU-9D32 instrument) captured at baseline and weeks 
12, 36, 48 and 60, using the proxy version for those aged under 7 years with additional guidance 
notes for parents of those aged under 5 years provided by the instrument developer), using linear 
interpolation and area under the curve with baseline adjustment.33 
 
Costs and outcomes will be discounted at recommended rates19 in weeks 53 to 60 to reflect the 
timeframe greater than 12 months. A regression-based approach (for instance seemingly-unrelated 
regression equations if assumptions are met,34 will be used to estimate the mean incremental cost 
and effects. Bootstrapping will explore uncertainty levels associated with the decision to adopt 
either treatment through the estimation of cost-effectiveness acceptability curves35. A specific 
health economics analysis plan will be written and finalised in advance of the trial database being 
locked. 
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Monitoring 
Study data is centrally monitored by the CTRC. A number of monitoring features are in place at the 
CTRC to ensure reliability and validity of the trial date, these are detailed in the ‘Trial Monitoring 
Plan’, available upon request. On-site monitoring visits can be triggered if necessary and will be 
carried out by either representatives of the CTRC or Sponsor. 
 
Ethics and dissemination 
Initial review and approval of the trial protocol along with the participant facing documents were 
submitted to the East of England – Cambridge East Ethics Committee, which gave a favourable 
opinion (16/01/2016). Any subsequent amendments to the protocol and/or participant facing 
documents will require ethical approval.  
 
Protocol Amendments 
Protocol amendments are assessed by the Trial Management Group and approved by the Sponsor, 
Research Ethics Committees and by the Regulatory Authorities in the UK and Ireland.  
 
Summary 
TREAT addresses key clinical questions for the management of children with severe atopic 
eczema using systemic medication, in particular whether there is a difference in speed of 
onset, effectiveness, side-effect profile and reduction in flares post-treatment between CyA 
and MTX, and, if so, the cost-effectiveness of the drugs. Furthermore, TREAT examines 
mechanistically how both drugs exert their anti-inflammatory profile systemically and in the 
skin.  
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Dissemination Policy 
Trial results 
The results from different centres will be analysed together and published as soon as possible. 
Individual clinicians must undertake not to submit any part of their individual data for publication 
without the prior consent of the TMG. Access to fully anonymised participant-level datasets and 
statistical codes can be made by requests to the TMG, once the final results of the trial have been 
published. 
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acting as co-applicants. TS led the NIHR Research for Patient Benefit application that funds the 
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form the basis of the writing committee and advise on the nature of the publications. The Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org) will be 
respected. 
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Trial Steering Committee:  
Independent members: Alison Layton (Chair, Consultant Dermatologist & Associate Medical Director 
for Research); Tim Burton (Patient & Public Representative); Michael Grainge (Statistician); Michael 
Arden-Jones (Dermatologist); Saskia King (Patient & Public Representative); Michael Perkin 
(Consultant Paediatric Allergist); Alain Taieb (Paediatric Dermatologist). Non-independent member: 
Carsten Flohr (Chief Investigator), 
 
Independent Data and Safety Monitoring Committee:  
Anthony Ormerod (Chair, Emeritus Professor in Dermatology, University of Aberdeen and Honorary 
Consultant Dermatologist NHS Grampian); Robert Chalmers (Honorary Consultant Dermatologist, 
Co-Chair and Managing Editor, Dermatology Topic Advisory Group, WHO ICD Revision Project); 
Xinxue Liu (Honorary Research Fellow). 
 
Trial Management Group: Amina Ahmed (Patient & Public Representative); Farhiya Ashoor (Trial 
Manager); Carsten Flohr (Chief Investigator, Chair); Anna Rosala-Hallas (Trial Statistician); Amy 
Holton (Sponsor Representative); Alan Irvine (Principal Investigator); Ashley Jones (Lead Statistician), 
Tracey Sach (Health Economist); Catherine Spowart (Supervising Trial Manager); Mandy Wan (Lead 
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Pharmacist); Charlotte Walker (Lead Research Nurse), Paula Williamson (Director of the Clinical Trials 
Research Centre) 
 
Principal Investigators: Suzannah August (Poole Hospital); Paula Beattie (Royal Hospital for Children, 
Glasgow); Sara Brown (Ninewells Hospital, Dundee); Mike Cork (Sheffield Children’s Hospital); Ben 
Esdaile (Whittington); Carsten Flohr (Guy’s & St Thomas’ Hospital); Joanna Gach (University Hospitals 
Coventry & Warwickshire); Emma Howard (Birmingham Children’s Hospital); Alan Irvine (Our Lady’s 
Children’s Hospital, Dublin);  Tess McPherson (Oxford University Hospitals); Donal O’Kane (Royal 
Victoria Hospital, Belfast); Jane Ravenscroft (Nottingham University Hospitals); Lindsay Shaw (Bristol 
Royal Hospital for Children). 
 
Co-Investigators: Caroline Allen (Oxford University Hospitals); Susannah Baron (Guy’s & St Thomas’ 
Hospital); Danielle Greenblatt (Guy’s & St Thomas’ Hospital); Robert Hearn (Ninewells Hospital, 
Dundee); Susannah Hoey (Royal Victoria Hospital, Belfast); Rachael Jarret (Oxford University 
Hospitals); Catherine Jury (Royal Hospital for Children, Glasgow); Charlie Mitchell (Poole Hospital); 
Ruth Murphy (Sheffield Children’s Hospital); Graham Ogg (Oxford University Hospitals); Alice Plant 
(Poole Hospital); Louise Newell (Bristol Royal Hospital for Children); Jothsana.Srinivasan (Nottingham 
University Hospitals), Emma Wedgeworth (Guy’s & St Thomas’ Hospital) 
 
Laboratory investigations: 
Nicholas Webb (Manchester Royal Infirmary) - provision of expertise on measurement and 
assessment of renal function relating to study drug administration; Leonie Taams (King’s College 
London) – immunology work; Luke O’Neil (Trinity College Dublin) – metabolomics; Irwin Mclean 
(University of Dundee) – FLG mutation analyses.  
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Table 1:  TREAT trial inclusion criteria 
 
1. Written informed consent for study participation obtained from the patient or parents/legal 
guardian, with assent as appropriate by the age/understanding of the patient 
 
2. Aged 2-16 years at the time of the screening and randomisation visit 
 
3. Diagnosis of severe, recalcitrant atopic eczema 
 
4. History of inadequate clinical response (in the opinion of the treating clinician) to 
potent topical corticosteroids on the body and moderate strength topical 
corticosteroids on the face. 
5. An objective (o)-SCORAD severity score of at least 30 
 
6. Participants must live within travelling distance of the recruiting centre 
 
7. Females of childbearing potential and males, who are sexually active, must commit 
to consistent and correct use of a highly effective method of contraception (e.g. 
combined hormonal contraception, intrauterine device, physical barrier or abstinence) 
for the duration of the trial and for 6 months after the last dose of study drug. 
 
8. Willingness to comply with study requirements 
 
9. Baseline visit within maximum of 2 weeks of the screening visit 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2: TREAT trial exclusion criteria 
 
1. Serious underlying medical condition 
 
2. Pregnant or nursing (lactating) females 
 
3. Any active and/or chronic infection at screening or baseline (randomisation) visit that, 
based on the investigator's clinical assessment, makes the subject an unsuitable 
candidate for the study 
 
4. Presence of moderate-to-severe impaired renal function as indicated by clinically 
significantly abnormal creatinine (≥ 1.5 x upper normal limit (ULN) for age and sex) 
AND eGFR <60ml/min/1.73m2 at screening visit 
 
5. Clinical evidence of liver disease or liver injury at screening visit as indicated by 
abnormal liver function tests such as AST, ALT, GGT, alkaline phosphatase, or serum 
bilirubin (must not exceed 1.5 x the upper limit value of the normal range for age and 
sex) 
 
6. Total WBC count <3x109/L, or platelets <150x109/L or neutrophils <1.5x109/L or 
haemoglobin <8.5 g/L at screening visit 
 
7. Blood pressure values > 95th percentile for age and sex at screening and baseline visit 
 
8. Received systemic corticosteroids within 14 days prior to screening visit and 28 days of 
baseline visit 
 
9. Received phototherapy within 4 weeks prior to screening visit and 6 weeks of the 
baseline visit 
 
10. Previous exposure to any biologic agents or systemic immuno-suppressive therapy, 
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except for oral corticosteroids for acute flare management 
 
11. Concomitant use of disease-modifying and/or immunosuppressive drugs 
 
12. Received live vaccines within 4 weeks prior to baseline visit 
 
13 Radiology report of abnormal chest x-ray at the screening visit (at the discretion of the 
PI/medically qualified physician) 
14 Receiving treatment with medicines that are substrates for the multidrug efflux 
transporter P-glycoprotein or the organic anion transporter proteins (OATP) for which 
elevated plasma concentrations are associated with serious and/or life-threatening 
events; this includes bosentan, dabigatran, etexilate, and aliskiren. 
15 Receiving treatment with products containing Hypericum perforatum (St. John's 
wort) 
16 Receiving oral treatment with tacrolimus, everolimus, sirolimus or lercandipine 
 
17 Currently participating in a conflicting study or participation in a clinical study involving 
a medicinal product in the last 28 days or less than 5 half-lives of the medicinal 
product prior to the screening visit 
18 Known hypersensitivity to methotrexate or ciclosporin products 
19  Insufficient understanding of the trial by the patient and/or parent/guardian 
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